1-3 of 3
Grace Cleary
Close
Sort by
Journal Articles

Ruxolitinib for pediatric patients with treatment-naïve and steroid-refractory acute graft-versus-host disease (REACH4)

Clinical Trials & Observations
Franco Locatelli, Hyoung Jin Kang, Benedicte Bruno, Virginie Gandemer, Fanny Rialland-Battisti, Maura Faraci, Yoshiyuki Takahashi, Katsuyoshi Koh, Henrique Bittencourt, Grace Cleary, Christine Rosko, Xuechan Li, Annie St. Pierre, Anirudh Cadapa Prahallad, Christina Diaz-de-Heredia
Journal: Blood
Blood blood.2023022565.
https://doi.org/10.1182/blood.2023022565
Published: 2024
Includes: Supplemental data
Journal Articles

Siremadlin, a Human Double Minute-2 (HDM2) Inhibitor, Added to Ruxolitinib after Suboptimal Response to Ruxolitinib Alone in Patients with Myelofibrosis: Results from Part 1 of the Phase 1/2 Adore Study

Florian H Heidel, Andrew Charles Perkins, Andreas Reiter, Carl C. Crodel, Caroline Hasselbalch Riley, María Teresa Gómez-Casares, Istvan Takacs, Heiko Becker, Thomas Lehmann, Olga Vinogradova, Kate Burbury, Alessandro M. Vannucchi, Vikas Gupta, Claire Harrison, Marielle Wondergem, Jean-Jacques Kiladjian, Grace Cleary, Angela Zhang, Bruyère Mahuzier, Jagannath Kota, Anirudh Prahallad, David M Ross
Journal: Blood
Blood (2022) 140 (Supplement 1): 590–593.
https://doi.org/10.1182/blood-2022-158501
Published: 2022
Journal Articles

Ruxolitinib in Pediatric Patients with Treatment- Naïve or Steroid-Refractory Acute Graft-Versus-Host Disease: Primary Findings from the Phase I/II REACH4 Study

Franco Locatelli, Hyoung Jin Kang, Bénédicte Bruno, Virginie Gandemer, Fanny Rialland, Maura Faraci, Yoshiyuki Takahashi, Katsuyoshi Koh, Henrique Bittencourt, Grace Cleary, Christine Rosko, Pantelia Roussou, Annie St. Pierre, Anirudh Prahallad, Cristina Díaz-de-Heredia
Journal: Blood
Blood (2022) 140 (Supplement 1): 1376–1378.
https://doi.org/10.1182/blood-2022-155708
Published: 2022